Literature DB >> 7545172

Differential binding of the NFE3 and CP1/NFY transcription factors to the human gamma- and epsilon-globin CCAAT boxes.

A E Ronchi1, S Bottardi, C Mazzucchelli, S Ottolenghi, C Santoro.   

Abstract

Naturally occurring nondeletional mutations affecting the distal CCAAT box of the human gamma-globin gene promoter result in hereditary persistence of fetal hemoglobin in adult life. Although the distal CCAAT box is the target of several factors, including CP1/NFY, CDP, GATA-1 and NFE3, only NFE3 binding activity is consistently sensitive to well characterized mutations in this region such as G-117-->A, C-114-->T, and delta 13 hereditary persistence of fetal hemoglobin. We extensively characterized the binding specificities of NFE3 and demonstrated that NFE3 has unique properties with respect to other CCAAT box-binding proteins. Affinity-purified NFE3 from erythroid K562 cells binds the distal but not the proximal human gamma-globin CCAAT box, the single CCAAT box of the human epsilon-globin promoter, and the proximal CCAAT box of the evolutionarily related Galago crassicaudatus gamma-globin gene. Within the epsilon-globin CCAAT box, NFE3 represents the major and almost exclusive binding activity. Disruption of such a binding site essentially inactivates the epsilon-globin promoter, suggesting that NFE3 plays an important role in the embryonic expression of this gene.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7545172     DOI: 10.1074/jbc.270.37.21934

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  18 in total

1.  Sp1 mediates cell proliferation-dependent regulation of rat DNA topoisomerase IIalpha gene promoter.

Authors:  J H Yoon; J K Kim; G B Rha; M Oh; S H Park; R H Seong; S H Hong; S D Park
Journal:  Biochem J       Date:  1999-12-01       Impact factor: 3.857

2.  The effect of chromatin structure on cisplatin damage in intact human cells.

Authors:  N P Davies; L C Hardman; V Murray
Journal:  Nucleic Acids Res       Date:  2000-08-01       Impact factor: 16.971

3.  Role of the duplicated CCAAT box region in gamma-globin gene regulation and hereditary persistence of fetal haemoglobin.

Authors:  A Ronchi; M Berry; S Raguz; A Imam; N Yannoutsos; S Ottolenghi; F Grosveld; N Dillon
Journal:  EMBO J       Date:  1996-01-02       Impact factor: 11.598

Review 4.  Evolution of hemoglobin loci and their regulatory elements.

Authors:  Sjaak Philipsen; Ross C Hardison
Journal:  Blood Cells Mol Dis       Date:  2017-08-09       Impact factor: 3.039

5.  Embryonic and fetal beta-globin gene repression by the orphan nuclear receptors, TR2 and TR4.

Authors:  Osamu Tanabe; David McPhee; Shoko Kobayashi; Yannan Shen; William Brandt; Xia Jiang; Andrew D Campbell; Yei-Tsung Chen; Chawn shang Chang; Masayuki Yamamoto; Keiji Tanimoto; James Douglas Engel
Journal:  EMBO J       Date:  2007-04-12       Impact factor: 11.598

6.  A zinc-finger transcriptional activator designed to interact with the gamma-globin gene promoters enhances fetal hemoglobin production in primary human adult erythroblasts.

Authors:  Andrew Wilber; Ulrich Tschulena; Phillip W Hargrove; Yoon-Sang Kim; Derek A Persons; Carlos F Barbas; Arthur W Nienhuis
Journal:  Blood       Date:  2010-02-26       Impact factor: 22.113

7.  SCF induces gamma-globin gene expression by regulating downstream transcription factor COUP-TFII.

Authors:  Wulin Aerbajinai; Jianqiong Zhu; Chutima Kumkhaek; Kyung Chin; Griffin P Rodgers
Journal:  Blood       Date:  2009-04-28       Impact factor: 22.113

8.  Regulation of embryonic/fetal globin genes by nuclear hormone receptors: a novel perspective on hemoglobin switching.

Authors:  A Filipe; Q Li; S Deveaux; I Godin; P H Roméo; G Stamatoyannopoulos; V Mignotte
Journal:  EMBO J       Date:  1999-02-01       Impact factor: 11.598

9.  Promoter-bound METTL3 maintains myeloid leukaemia by m6A-dependent translation control.

Authors:  Isaia Barbieri; Konstantinos Tzelepis; Luca Pandolfini; Junwei Shi; Gonzalo Millán-Zambrano; Samuel C Robson; Demetrios Aspris; Valentina Migliori; Andrew J Bannister; Namshik Han; Etienne De Braekeleer; Hannes Ponstingl; Alan Hendrick; Christopher R Vakoc; George S Vassiliou; Tony Kouzarides
Journal:  Nature       Date:  2017-11-27       Impact factor: 49.962

10.  A genome-editing strategy to treat β-hemoglobinopathies that recapitulates a mutation associated with a benign genetic condition.

Authors:  Elizabeth A Traxler; Yu Yao; Yong-Dong Wang; Kaitly J Woodard; Ryo Kurita; Yukio Nakamura; Jim R Hughes; Ross C Hardison; Gerd A Blobel; Chunliang Li; Mitchell J Weiss
Journal:  Nat Med       Date:  2016-08-15       Impact factor: 53.440

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.